🚀 Corbus Pharmaceuticals (Ticker: CRBP) made headlines on January 26th, 2024, as its shares skyrocketed an astonishing 207% following the groundbreaking Phase 1 Cancer Study results for patients with nectin-4 positive tumors. 🌟
In this video, we delve into the incredible journey of CRBP stock, breaking down the technical analysis that fueled its meteoric rise. The stock hit a psychological resistance level just below $40 before retracing to the .618 Fibonacci level around $18 and finding support. Currently settling around the $24-$25 .382 Fibonacci retracement level, CRBP appears poised for further gains.
📈 We explore the key levels to watch, with a critical focus on the $29 breakout point, which could propel the stock to $35 and potentially even $40. A breach of the $40 resistance level might pave the way for an exciting journey into the $60 to $80 range.
Whether you're a seasoned trader or a curious investor, this video provides valuable insights into CRBP's recent surge and potential future movements. Don't miss out on understanding the technical factors influencing the stock's trajectory and the possible scenarios that could unfold in the coming weeks.
In this video, we delve into the incredible journey of CRBP stock, breaking down the technical analysis that fueled its meteoric rise. The stock hit a psychological resistance level just below $40 before retracing to the .618 Fibonacci level around $18 and finding support. Currently settling around the $24-$25 .382 Fibonacci retracement level, CRBP appears poised for further gains.
📈 We explore the key levels to watch, with a critical focus on the $29 breakout point, which could propel the stock to $35 and potentially even $40. A breach of the $40 resistance level might pave the way for an exciting journey into the $60 to $80 range.
Whether you're a seasoned trader or a curious investor, this video provides valuable insights into CRBP's recent surge and potential future movements. Don't miss out on understanding the technical factors influencing the stock's trajectory and the possible scenarios that could unfold in the coming weeks.